Na Cocer Peptides bin rayt am 
13 dez bifo
ƆL DI ATIKUL ƐN PRODƆKT INFƆMƐSHƆN WE DƐN GI NA DIS WƐBSAYT NA FƆ ƆL FƆ DI INFƆMƐSHƆN ƐN FƆ EDYUKESHƆN.
Di prɔdak dɛn we dɛn gi na dis wɛbsayt na fɔ in vitro risach nɔmɔ. in vitro risach (Latin: *in glas*, we min insay glas) dεn de du am ausayd mכtalman bכdi. Dɛn prɔdak ya nɔto mɛrɛsin, dɛn nɔ gɛt di aprɔval frɔm di US Food and Drug Administration (FDA), ɛn dɛn nɔ fɔ yuz dɛn fɔ protɛkt, trit, ɔ mɛn ɛni mɛrɛsin, sik, ɔ sik. Di lɔ nɔ gri fɔ mek dɛn put dɛn tin ya insay mɔtalman ɔ animal bɔdi ɛni we.
Ovaviu fɔ Semaglutid
Semaglutid na wan nyu glukagon lεk pεptida-1 rεsεptכr agonist (GLP-1 RA). glukagon-layk pεptida-1 (GLP-1) na כmon we di mכtalman bכdi de kכl nכmal wan we de ple imכtant rol fכ rεgεl di glukכs na di bכdi. we di blכd glukכs lεvεl go כp, di GLP-1 de kכmכt εn i de rεgεl di blכd glukכs lεvεl tru difrεn mεkanism dεm. Bɔt pan di wan dɛn we gɛt dayabitis, bɔku tɛm di GLP-1 sekreshɔn nɔ kin du ɔ di ifɛkt dɛn we i kin gɛt nɔ kin du. Semaglutid de biεn di GLP-1 rεsεpכta dεm, we de miks di fysiolojikal ifekt dεm we GLP-1 de gi, we de mek i de εksyεrt di tεrapi ifekt fכ dayabεtis εn weit mεnejmεnt.
Fig 1 Tritmɛnt fɔ fat ɛn di impak we dɛn gɛt pan di wet we pɔsin de lɔs
Di Rol we Semaglutid Gɛt pan Dayabitis Tritmɛnt
Fɔ mek di insulin we de kɔmɔt na di bɔdi go bifo
כnda di fysiolojikal kכndishכn dεm, we di blכd glukכs lεvεl de go כp, di εnteroεndokrin sεl dεm na di intestin de sekret GLP-1. GLP-1 de biεn di GLP-1 rεsεpכta dεm na di sεf fכ di pankrεas β sεl dεm, we de aktibכt wan siriכs signal path fכ inkrεs insulin sekreshכn. semaglutid kin spεshal biεn bak to GLP-1 rεsεpכta dεm na di sεf pan di pankrεas β sεl dεm, we de mek insulin sekreshכn insay wan we we dipεnd pan glukכs kכnsantreshכn. dis min se we di blכd glukכs lεvεl go כp, Semaglutid de εfεktiv fכ protεkt insulin rilis fכ lכs di blכd glukכs lεvεl; we di blכd glukכs lεvεl de insay di nכmal rεnj, in ifekt fכ protεkt insulin sekreshכn de wik, we de ridyus di risk fכ haypoglycemia. Stɔdi dɔn sho se afta dɛn dɔn trit di sikman dɛn wit Semaglutid, di insulin sekreshɔn lɛvɛl we di sikman dɛn gɛt kin bɛtɛ bad bad wan, ɛn dɛn kin kɔntrol di glukɔs lɛvɛl na di blɔd fayn fayn wan.
Figure 2: Wan apstrim weit-sεntrik aprכch vεrs mכr dכwnstrכm, glukכs-sεntrik, εn kכdiכmεtabolik aprכch. di tεrapi dεm we de bays pan inkrεtin dεn dכn כlrεdi de aktif na di mכst כpstrim stεp.
difrεnt frכm tradishכnal insulin sekretagכg dεm, lεk sulfonylureas, we de kכntinyu fכ mek insulin sekreshכn i nכ mata di blכd glukכs lεvεl εn kin inkrεs di risk fכ haypoglycemia, Semaglutid in glukoz-kכnsantreshכn-dipεndεnt insulin sekreshכn prכpati dεm de mek i ebul fכ lכs di blכd glukכs lεvεl fayn fayn wan we i de ridyus di insidεns fכ haypoglycemia, we de gi wan opshכn we sef εn mכr ifektiv bכdi glukכs kכntrכl pipul dɛn we gɛt dayabitis.
Inhibishכn fכ glukagon sekreshכn
Glucagon na כmon we di pankrias α sεl dεm de kכl we de εlevεt di glukכs lεvεl na di bכdi, we de akt opכsite to insulin. pan di wan dεm we gεt dayabitis, bכku tεm dεn nכ de stɔp di glukכn we de kכmכt ivin we di glukכs lεvεl na di bכdi go כp. semaglutid de akt pan GLP-1 risεptor dεm pan pankrεas α sεl dεm fכ inhεbit glukagon sekreshכn. we di glukoz sekreshכn dכn dכn, di liva in glycogenolysis εn gluconeogenesis prכsεs dεm de inhεbit, we de ridyus di εndojεnik glukכs prodakshכn εn fכ lכs di bכdi glukכs lεvεl mכr. Sayɛnsman dɛn dɔn kɔnfyus se pan tayp 2 dayabitis pasɛnt dɛn we dɛn trit wit Semaglutid, di plasma glukɔs lɛvɛl kin rili dɔŋ, we kin ridyus di hepatik glukɔs autput fayn fayn wan ɛn i kin ple impɔtant pat fɔ mek di blɔd glukɔs lɛvɛl stebul.
Dilay fɔ ɛmti di gastric
semaglutid de akt pan GLP-1 risεptor dεm na di gεstrointestinal trakt fכ slo di gεstrik εmpti. We di bɛlɛ ɛmti kwik kwik wan, dat kin mek di it go insay di smɔl intestin kwik kwik wan, we kin mek di glukɔs we de na di blɔd go ɔp kwik kwik wan. bay we dεn delay di gεstrik εmpti, di it de de na di bεlε fכ lכng tεm εn i de go insay di sכmכl intestin sloslo, we de mek di glukכs de tek mכr sכmtεm sכmtεm εn i nכ de mek di blכd glukכs lεvεl go shap shap afta dεn it. dis ifekt de εp fכ mεnten stebul postprandial bכdi glukכs lεvεl εn rεdכks di bכdi glukכs fכlt. Insay sɔm klinik trayal dɛn, di pasɛnt dɛn we dɛn trit wit Semaglutid bin ɛkspiriɛns wan big ridɔkshɔn pan di postprandial blɔd glukɔs pik ɛn smɔl smɔl blɔd glukɔs fluktueshɔn, we impruv di ɔvala blɔd glukɔs kɔntrol kwaliti. Apat frɔm dat, di delay we di gastric ɛmti kin mek pɔsin fil se i ful-ɔp, we kin ɛp fɔ ridyus di it we i de it ɛn dat kin ɛp fɔ kɔntrol di glukɔs na di blɔd ɛn fɔ manej di wet frɔm ɔda angle.
Figure 3: Mekanism fכ Semaglutid fכ di Mεnεjmεnt fכ Obesity
Improving β-Sεl Fכnshכn
di krכnik haypa glycemia kin pwεl di pankrεas β sεl dεm, we kin mek di fכnshכn dεklin sכmtεm. semaglutid nכ de כnli lכs di blכd shuga bay we i de protεkt insulin sekreshכn bכt i de protεkt εn ripεr pankrεas β sεl dεm, we de mek di β sεl dεm wok fayn. sayɛns stכdi dεn sho se semaglutide kin aktibכt sכm intasεlulyar signal path dεm fכ promuot β-sεl proliferashכn, inhεbit β-sεl apoptosis, we de mek di nכmba εn fכnshכn fכ β-sεl dεm go inkrεs. insay animal εkspεriεns εn sכm klinik stכdi dεm, dεn si se afta dεn yuz Semaglutid, di insulin sekreshכn kapasiti fכ β sεl dεm bin εnhans, εn insulin rεsistεns bin impruv. Dis na big impɔtant tin fɔ di lɔng tɛm tritmɛnt fɔ tayp 2 dayabitis, bikɔs i de ɛp fɔ slo di sik ɛn ridyus di risk fɔ gɛt dayabitis kɔmplikeshɔn.
Aplikeshɔn fɔ Semaglutid insay Dayabitis Tritmɛnt
Semaglutid gɛt difrɛn we fɔ yuz am fɔ trit dayabitis. Fɔ di nyu wan dɛn we dɛn dɔn no se gɛt tayp 2 dayabitis, if di blɔd glukɔs lɛvɛl nɔ rili ɔp ɛn nɔ klia akyu kɔmplikeshɔn ɔ ɔda siriɔs kɔmɔrɔbiditi nɔ de, dɛn kin tink bɔt fɔ tek wan tritmɛnt wit Semaglutid. Klinik stכdi dεm sho se sכm nyu sik pipul dεm we dεn nכ no di sik bin gεt bכku dכn dכn pan hεmoglobin A1c (HbA1c) lεvεl dεm εn dεn weit lכs afta wan tεm we dεn tek wan tεrapi. Fɔ ɛgzampul, insay di PIONEER siriɔs stɔdi, di pasɛnt dɛn we dɛn trit wit ɔral Semaglutid monotɛrapi bin ɛkspiriɛns wan big ridyushɔn pan di HbA1c lɛvɛl we dɛn kɔmpia am wit di plasɛbo grup, wit gud sef ɛn tolɛrabiliti. Di bɛnifit fɔ wan tritmɛnt na dat i de avɔyd di risk fɔ mek di mɛrɛsin dɛn we gɛt fɔ du wit kɔmbayn tɛrapi, ɛn di we aw dɛn de gi am we rili simpul kin ɛp fɔ mek di pɔsin kɔntinyu fɔ fala di tritmɛnt.
Yu kin yuz semaglutid bak wit ɔda mɛrɛsin dɛn. We dɛn put am togɛda wit mɛtfɔmin, we na fɔs layn mɛrɛsin fɔ tayp 2 dayabitis, i de ɛp fɔ mek di insulin nɔ de wok fayn ɛn i de mek di glukɔs we de kɔmɔt na di epatik nɔ bɔku. Di tu mɛrɛsin dɛn gɛt kɔmplimɛnt mɛkanism fɔ akshɔn, we de mek i ebul fɔ kɔntrol di glukɔs na di blɔd mɔ fayn fayn wan. stכdi dεn sho se dis kכmbaynshכn rεjim de lכs di HbA1c lεvεl mכr εn i de rεsult in mכr pronכns weit lכs. Fɔ ɛgzampul, insay sɔm klinik trayal dɛn, di pasɛnt dɛn we dɛn trit wit mɛtfɔmin we ad Semaglutid bin gɛt big ridɔkshɔn pan HbA1c lɛvɛl kɔmpia to di wan dɛn we kɔntinyu fɔ gɛt mɛtfɔmin monotɛrapi, wit ɔda wet lɔs, we nɔ bin gɛt bɔku inkris pan di risk fɔ di haypoglycemia. Dis rijim fayn fɔ pasɛnt dɛn we dɛn nɔ kin kɔntrol dɛn blɔd glukɔs lɛvɛl fayn fayn wan wit mɛtfɔmin monotɛrapi.
Fɔ di wan dɛn we gɛt tayp 2 dayabitis we gɛt ay glukɔs na dɛn blɔd ɛn we nid insulin tɛrapi, fɔ ad Semaglutid to insulin tɛrapi kin ridyus di insulin doz. Insay insulin tritmɛnt, bɔku tɛm di sik pipul dɛn kin gɛt prɔblɛm dɛn lɛk fɔ gɛt bɔku bɔku bɔdi ɛn fɔ gɛt mɔ glycemia. we dεn yuz am togɛda, di ifekt dεm we Semaglutid de gi fכ mek insulin sekreshכn εn inhibit glukagon sekreshכn kin mek yu yuz insulin fayn fayn wan, ridyus di doz, εn dat kin mek i lכs di risk fכ weit gεn εn haypoglycemia. Fɔ ɛgzampul, insay sɔm klinik stɔdi dɛm, di pasɛnt dɛm we ad Semaglutid to dɛn insulin tɛrapi bin gɛt avɛrej ridɔkshɔn pan insulin doz, wit mɔ dɛkɛshɔn pan HbA1c lɛvɛl, weit lɔs, ɛn ridɔkshɔn pan di frɛkuɛns fɔ haypoglycemia episɔd.
Yu kin yuz semaglutid bak wit ɔda antidiabetic drɔgs lɛk SGLT2 inhibito dɛn. SGLT2 inhibito dεm de lכs di blכd glukכs bay we dεn de protεkt di glukכs kכmכt na di urine. di kכmbaynshכn fכ di tu kin impruv bכdi glukכs kכntrכl mכr tru difrεn mεkanism dεm εn i kin gεt sinagεstik ifekt dεm bak pan wet mεnejmεnt.
Di rol we Semaglutid de ple pan wet mɛnejɛmɛnt
Fɔ mek pɔsin nɔ want fɔ it
semaglutid de akt pan GLP-1 risεptor dεm na di sεntri nεv sεstem, patikyular insay di haypothalamus. di haypothalamus na wan kכl rijyכn na di bכdi fכ rεgεl di apεtit εn εnεji bεlε. afta i biεn di GLP-1 rεsεpכta dεm na di haypothalamus, di sεmaglutayd kin rεgεl di rilis fכ nyuropεptida dεm, lεk fכ ridyus di sekreshכn fכ nyuropεptida Y (NPY), we na strכng apetit-stimulating fכktכ. apat frכm dat, Semaglutid kin inkrεs di aktiviti fכ proopiomelanocortin (POMC) nyuron dεm, we in aktibכshכn de jεnarεt satiety signal dεm. Tru dεn mεkanism dεm ya, Semaglutid de εfεktivli sכpres di apεtit, we de mek di sik pipul dεm rεdכks di it we dεn de it. Insay klinik trial, di wan dɛn we fat ɔ we gɛt bɔku bɔku bɔdi we de yuz Semaglutid bin ripɔt se dɛn nɔ bin want fɔ it bɛtɛ ɛn dɛn nɔ bin de it bɛtɛ tin fɔ it, we bin le di fawndeshɔn fɔ mek dɛn lɔs dɛn wet.
Di mɔni we dɛn de spɛn pan ɛnaji
apat frכm we i de sכpres di apεtit, Semaglutid kin infכlכ di εnεji mεtabolism, we de inkrεs di εnεji we i de spεnd. rεsכch sho se Semaglutid kin inkrεs di enεji we i de spεnd bay we i de rεgεl di aktiviti fכ di brawn adipos tisu. brawn adipose tisu na spεshal tכp fεt tisu we in praymar fכnshכn na fכ kכnsכm enεji tru tεmכjεnεsis. semaglutid kin aktibכt sכm signal path dεm na brawn adipos tisu, we de protεkt fεt asid כksidεshכn εn tεmכjεnεsis. apat frכm dat, Semaglutid kin infכlכ di enεji mεtabolism insay tisu dεm lεk mכsul, we de inkrεs di enεji we dεn de spɛn ivin we i de rεst. fכ egzampl, insay animal εkspεriεns, afta dεn gi Semaglutid, di animal dεm in enεji mεtabolism rεt inkrεs, εn dεn bכdi wet dכn dכn ivin we di it we dεn de it bin de di sem, we sho se Semaglutid de ple fayn rol fכ mεnejmεnt di wet bay we i de inkrεs di εnεji we dεn de spɛn.
Rεgulεshכn fכ di mεtabolism fכ fεt
Semaglutid gεt rεgεdyushכn ifekt bak pan fεt mεtabolism. I kin mek di fat brok, i kin mek di fat nɔ bɔku, ɛn i kin mek i nɔ ebul fɔ kip di fat. insay di liva, Semaglutid kin inhεbit di aktiviti fכ di εnzym dεm lεk fεt asid sεntez, we de ridyus di fεt asid sεntez. apat frכm dat, insay adipos tisu, Semaglutid kin mek di fεt brok dכn, inkrεs di rilis fכ fri fεt asid dεm, εn i kin mek dεn go insay di maytochכndria fכ כksidεtiv brεk dכwn, we de mek di fεt stכrej dכn. Klinik stכdi dεn sho se afta wan tεm we dεn trit di sikman wit Semaglutid, di fεt we de insay di sikman in bכdi, spεshal fεt we de insay di vishכnal fεt, de dכn. dis nכ de כnli εp fכ lכs di wet bכt i gεt bכku implεkshכn fכ impruv mεtabolik sεndrכm εn ridyus di risk fכ kכdivaskyul sik.
Aplikeshɔn fɔ Semaglutid insay Weyt Manejmɛnt
Fɔ di wan dɛn we fat ɔ we gɛt bɔku bɔku bɔdi we gɛt sik dɛn we gɛt fɔ du wit am
Semaglutid gεt klia tכgεt pכpulεshכn fכ weit mεnejmεnt. Fɔ fat pasɛnt dɛn we gɛt BMI ≥30 kg/m² ɔ pasɛnt dɛn we gɛt bɔku bɔku bɔdi we gɛt BMI ≥27 kg/m² ɛn at le wan sik we gɛt fɔ du wit yu wet (lɛk aypatɛnshɔn, tayp 2 dayabitis, ɔ aypa kɔlɔstrelemia), na fayn mɛrɛsin fɔ kɔntrol yu wet. Di STEP siriɔs klinik trayal dɛn sho se di wan dɛn we dɛn trit dɔn lɔs bɔku bɔku wet. Insay di STEP 1 stɔdi, di pasɛnt dɛn we dɛn trit bin ajɔst wan avɛj wet lɔs we na lɛk 15% ova 68 wik, we di plesibo grup bin lɔs lɛk 2.4% nɔmɔ. Dɛn rizɔlt ya sho se i kin ɛp di wan dɛn we fat ɔ we gɛt bɔku bɔku bɔdi we gɛt ɔda tin dɛn we gɛt fɔ du wit dis, fɔ mek dɛn nɔ gɛt bɔku bɔku bɔdi ɛn fɔ lɔng tɛm, i kin mek dɛn gɛt wɛlbɔdi, ɛn i kin mek dɛn nɔ gɛt bɔku sik dɛn we dɛn kin gɛt we dɛn fat.
Kɔmbayn wit layf stayl intavɛnshɔn
insay wet mεnejmεnt, dεn kin yus Semaglutid in kכmbaynshכn wit layf stayl intavεnshכn, inklud fכ ridyus kalori intake εn inkrεs fכshal aktiviti. If fɔ lɛf fɔ it bɔku bɔku it de dipen pan mɛrɛsin nɔmɔ ɛn nɔ chenj di we aw pɔsin de liv in layf we nɔ fayn, bɔku tɛm di tin dɛn we kin apin nɔ kin kɔntinyu fɔ de. di kכmbaynshכn fכ di tu we dεm gεt wan sinajεstik ifekt: di mεdikeshכn de sכpres di apεtit εn i de inkrεs di εnεji we yu de spεnd, we di it kכntrכl de rεdכks di kalori dεm we yu de it εn inkrεs fכs fכs aktiviti de bכst di εnεji mכr, we de mek yu lכs mכr signifyant εn sustained weit. Fɔ ɛgzampul, insay sɔm klinik prɔsis, di pasɛnt dɛn we de fala wan lɔw-kalori it plan we wan nyutrishɔnist dɔn mek ɛn inkrisayz dɛn wik aerobic ɛksɛsayz tɛm we dɛn de gɛt tritmɛnt kin gɛt bɛtɛ bɛtɛ wet lɔs autkam pas di wan dɛn we de abop pan mɛrɛsin ɔ layf stayl intavɛnshɔn nɔmɔ. Dis kɔmbayn we fɔ du tin de ɛksplen di impɔtants fɔ kɔmprɛhnsiv mɛnejɛmɛnt insay di wet mɛnejɛmɛnt, fɔ ɛp di sikman dɛn fɔ mek dɛn gɛt wɛlbɔdi layf ɛn fɔ gɛt lɔng tɛm we dɛn fɔ kɔntrol dɛn wet.
Dɔn
Semaglutid de sho se i gɛt bɔku pɔtnɛshɛl pan ɔl tu di tritmɛnt fɔ dayabitis ɛn di wet mɛnejɛmɛnt. Insay dayabitis tritmɛnt, i kin kɔntrol di glukɔs na di blɔd fayn fayn wan tru bɔku bɔku we dɛn, i kin mek di β-sɛl dɛn wok fayn, ɛn dɛn kin yuz am as wan tritmɛnt ɔ dɛn kin yuz am wit ɔda mɛrɛsin dɛn we de agens dayabitis. Insay di wet mɛnejɛmɛnt, i de stɔp di apɛtit, i de mek yu spɛn mɔ ɛnaji, ɛn i de rigul di fat mɛtabolism, we de mek i fayn fɔ di wan dɛn we fat ɔ we gɛt bɔku bɔku bɔdi we gɛt di sik dɛn we gɛt fɔ du wit am. We dɛn put am togɛda wit di tin dɛn we pɔsin kin du fɔ liv in layf, i kin mek i gɛt bɛtɛ tin fɔ du.
Sos dɛn we dɛn pul
[1] Salvador R, Moutinho CG, Sousa C, ɛn ɔda pipul dɛn. Semaglutid as a GLP-1 Agonist: Wan Brekthrough in Obesiti Tritmεnt[J]. Famasiutik, 2025,18(3).DOI:10.3390/ph18030399.
[2] Memon A, Tehrim M, Kumari B. Semaglutid: nyu dawn fɔ di wan dɛn we gɛt dayabitis[J]. J ɔ rnal ɔ f di Pakistan Mɛdikal Assosiayshɔn, 2023,73(3):721.DOI:10.47391/JPMA.7558.
[3] Colin IM, Gérard K M. Wans-wik 2.4 mg Semaglutid fכ Weyt Mεnejmεnt in Obesiti: Wan Gεm Chenj?[J]. Touchrev Ɛndokrinɔl, 2022,18(1):35-42.DOI:10.17925/EE.2022.18.1.35.
[4] Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): wan nyu weit lɔs drɔg fɔ krɛs wet mɛnejɛmɛnt[J]. J ɔ rnal ov Inv ɛ stigetiv Mɛdisin, 2022,70(1):5-13.DOI:10.1136/jim-2021-001952.
[5] Mares AC, Chatterjee S, Mukherjee D. Semaglutid fכ weit lכs εn kכdiכmεtabolik risk rεdukshכn in כvaweit/obesiti[J]. Kɔrɛnt Opinion in Kadiɔlɔji, 2022,37(4):350-355.DOI:10.1097/HCO.0000000000000955.
[6] Chudleigh RA, Bain S C. Semaglutid injεkshכn fכ di tritmεnt fכ big pipul dεm wit tayp 2 dayabεtis[J]. Ekspɛkt Rivyu fɔ Klinik Famakɔlɔji, 2020,13(7):675-684.DOI:10.1080/17512433.2020.1776108.
[7] Gomez-Peralta F, Abreu C. Profayl fכ semaglutide in di mεnejmεnt fכ tayp 2 dayabεtis: disayn, divεlכpmεnt, εn ples in tεrapi[J]. Drug Des Divɛl Tɛr, 2019,13:731-738.DOI:10.2147/DDDT.S165372.
[8] Hedrington MS, Davis S N. Oral semaglutide fכ di tritmεnt fכ tayp 2 dayabεtis[J]. Ekspɛkt Opinion Pan Famakotɛrapi, 2019,20(2):133-141.DOI:10.1080/14656566.2018.1552258.
Prodak we de fɔ yuz fɔ risach nɔmɔ:
